Babu Yarlagadda S's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Nov 16, 2022
- Accession no.
- 0001127602-22-025761
- Filed
- Nov 16, 2022
- Trade date
- Nov 14, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $437.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Babu Yarlagadda SCIK 0001452635 | Officer (Chief Discovery Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2022 | Common Stock | MOption exerciseAcquired | +50,000 | $1.42 | +$71,000 | 280,056 | Direct | |
| Nov 14, 2022 | Common Stock | MOption exerciseAcquired | +50,000 | $1.42 | +$71,000 | 330,056 | Direct | |
| Nov 14, 2022 | Common Stock | SSaleDisposed | −31,515 | $13.88 | −$437,428.2 | 298,541 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2022 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 0 | Direct | |
| Nov 14, 2022 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.